[Main Text] 1
Introduction 2 The presence of Lewy Neurites and Lewy Bodies -intraneuronal inclusions containing aggregated and 3 phosphorylated (at serine 129; S129) α-syn as a main component -is a characteristic feature in the 4 brains of both sporadic and familial Parkinson's Disease (PD) patients (Anderson et al., 2006; Spillantini 5 et al., 1997; Wong and Krainc, 2017) . 6
Progression of Lewy pathology is evident already at the early stage of PD and coincides with 7 compromised neuronal functions putatively by causing synaptic and mitochondrial dysfunction, cell 8 stress, and deregulation of protein degradation pathways, which lead to neurodegeneration and 9 disability in PD patients (Braak et al., 2003; Lashuel et al., 2013; Venda et al., 2010; Wong and Krainc, 10 2017) . As α-syn aggregation is believed to be one of the earliest events in PD progression, treatments 11 attenuating α-syn, aggregation and pathology spread should be applied to the patients at the earliest 12 possible PD stages. Conversely, for late stage PD patients, transplantation of midbrain neural 13 progenitors holds a great promise for cure (Barker et al., 2018) . However, neurons transplanted into 14 the brains of PD patients can accumulate Lewy Bodies (LBs), presumably, through transmission of 15 misfolded prion-like proteins present in the PD patient's brain (Kordower et al., 2008; Li et al., 2008) . 16
Therefore, treatments attenuating α-syn phosphorylation, aggregation and spread could be valuable 17 also for late stage PD patients after transplantation therapy. 18
Glial cell line-derived neurotrophic factor (GDNF) promotes survival of mature dopamine (DA) neurons 19 in vitro and in vivo (Kopra et al., 2017; Lin et al., 1993; Moore et al., 1996) . GDNF binds and transduces 20 signal through multiple receptors: RET tyrosine kinase (Durbec et al., 1996) , Neuronal Cell Adhesion 21
Molecule (NCAM) (Paratcha et al., 2003) , syndecan-3 (Bespalov et al., 2011) , N-cadherin and integrins 22
All drug treatments followed the same schedule (Fig. 5E) . A proposed simplified cascade of signaling 1 events leading to reduced pathological α-syn accumulation in DA neurons upon RET activation is 2 depicted in Fig. 5F . 3 4 Discussion 5
Our data for the first time demonstrate that GDNF can slow or even stop accumulation of α-syn in 6 models recapitulating spreading of misfolded α-syn -a neuropathological hallmark of PD. Importance 7 of our finding is that for the first time we demonstrate the connection between two major therapeutic 8 approaches for PD -neuroprotection through stimulation of trophic pathways and slowing down the 9 spread of Lewy pathology. Therapies based on either of aforementioned approaches had been and/or 10 are planned to be tested in clinic (clinical trials ##NCT03100149, NCT03318523, NCT03716570, 11 NCT02618941, NCT02267434, NCT03611569, NCT03272165, NCT01621581, NCT03295786, 12 NCT01621581) (Huttunen and Saarma, 2019; Jankovic et al., 2018; Paul and Sullivan, 2019; Weihofen 13 et al., 2019) . Our data for the first time indicate a possibility to design neurotrophic signaling-based 14 therapies with two-fold mode of action addressing both survival and Lewy pathology spread. However, 15 such therapies might require modified clinical approaches e.g. treatment of early stage patients, which 16 was already suggested as a way to increase efficiency of neurotrophic therapies for PD (Paul and 17 Sullivan, 2019) . Identification of such patients will be increasingly feasible with the advancement of 18 diagnostic methods for the early detection of α-syn oligomers (e.g. in skin biopsy samples (Doppler et 19 al., 2017) or from cerebrospinal fluid (Kang et al., 2019) ). 20
Importantly, there is ongoing controversy if GDNF therapies can at all be effective in PD with Lewy 21 pathology. Decressac et al. have claimed that in rat α-syn overexpression models and PD patients with 22
Lewy pathology α-syn accumulation can lead to downregulation of Ret, which impairs GDNF receptor 1 signaling thus rendering GDNF treatments ineffective (Decressac et al., 2012; Decressac et al., 2013; 2 Decressac et al., 2011) . However, later studies have not observed RET downregulation neither in PD 3 animal models nor in post mortem PD patient brains (Su et al., 2017) . In addition, PET imaging in recent 4 GDNF clinical trials showed clear effects of GDNF in PD patients -i.e. increase in 18F-DOPA uptake 5 (Whone et al., 2019a) . While interpreting results of Decressac et al., it is important to note that they 6 were done in models utilizing AAV-mediated overexpression of α-syn, which might have resulted in very 7 high α-syn expression levels (Hoffer and Harvey, 2011) . This model does not recapitulate spreading 8 nature of Lewy pathology; however, might represent a late stage PD or some subpopulation of patients. 9
In contrast, our studies utilized model of early, spreading Lewy pathology. Considering our finding that 10 GDNF/RET signaling limits accumulation of misfolded α-syn, it is intriguing to speculate that after 11 reaching certain threshold level, misfolded α-syn accumulation and impairment of GDNF/RET signaling 12 might form a vicious cycle with misfolded α-syn impairing GDNF/RET action thus leading to even faster 13 progression of Lewy pathology. 14 The progression of LB-like pathology, i.e. accumulation of aggregated, phosphorylated at Ser129 α-syn 15 in our midbrain cultures, was similar to what was observed in other publications (Volpicelli-Daley et al., 16 2014; Volpicelli-Daley et al., 2011) . In the time frame of our experiments, we did not observe any loss 17 of DA neurons. Other studies also did not report DA cell loss at 7 days post-PFFs, and modest cell loss 18 was observed after longer periods (i.e. 14 days post PFFs) and/or additional neurotoxic insult to the 19 cells (Tapias et al., 2017; Volpicelli-Daley et al., 2014) . Moreover, the lack of cell death at the early time 20 points after induction of the pathological α-syn aggregation is consistent with reports showing that 21 while the rodents injected with PFFs develop robust α-syn aggregation, such loss of DA neurons was 22 observed only several months after PFF treatment. Similarly, the transgenic mice overexpressing α-syn 1 exhibit DA neurodegeneration only at old age (Lee et al., 2002; Luk et al., 2012; Paumier et al., 2015; 2 Richfield et al., 2002; Thiruchelvam et al., 2004) . Accordingly, motor abnormalities in PFF-treated or α-3 syn overexpressing animals were observed after several months post-injection of PFFs or at advanced 4 age. Despite years of research, clear cause of DA neurons' loss in PD remains undefined, with support 5 gained by the "multiple hit" hypothesis suggesting that neurodegeneration in PD is caused by a 6 combination of several factors, one of which is α-syn misfolding (Surmeier et al., 2017) . Moreover, 7 recent research on human patient iPSC-derived DA neurons shows that they are more vulnerable than 8 mouse DA neurons due to higher DA content and even then, robust pathological phenotypes are only 9 observed after very long (several months) culturing periods and/or introduction of multiple detrimental 10 factors, with α-syn-related pathology among them (Burbulla et al., 2017) . Our data is in line with this 11 research supporting evidence that aggregation of α-syn might be just one of multiple hits necessary for 12 the demise of DA neurons in PD. 13
In our experiments, we demonstrated that GDNF is effective at reducing Lewy pathology progression 14 at least at early time points after PFFs application. Efficacy of the GDNF treatment in vivo was much 15 greater than that observed in vitro, leading to almost complete abolishment of LB-like aggregates in the 16 SN of mice overexpressing GDNF at the region. This might be due to high levels of GDNF achieved in 17 vivo by AAV-hGDNF expression, as we and others have previously observed (Kirik et al., 2000; Penttinen 18 et al., 2018; Tenenbaum and Humbert-Claude, 2017) . Another explanation is that the cultured cells 19 were exposed to constant, high PFF concentration, which resulted in much faster acquisition of 20 pathology, while in vivo experiments rely on uptake of PFFs by DA axons in the striatum and transport 21 of PFFs into the cell body, resulting in much slower development of α-syn aggregates in DA neuron 22 soma, which was more efficiently prevented by GDNF. Altogether, these data suggest that while in our 1 in vitro setup GDNF is moderately effective, it reliably protected DA neurons in vivo, at least when 2 administered before the development of LB pathology. 3 GDNF exerts its function through several receptors with partially overlapping effector pathways. Our 4 data demonstrate that RET is indispensable for effects of GDNF in reducing pαSyn accumulation. 5
Moreover, overexpression of different isoforms of RET shows that constitutively active RET mutant is 6 sufficient to reduce pαSyn accumulation. Constitutively active RET receptor was previously shown to 7 exert protective effects on DA neurons (Mijatovic et al., 2011) ; however, its ability to reduce progressive 8 accumulation of pαSyn has never been studied before. Our findings strongly support the validity of RET 9 as a target for disease-modifying therapy for PD. Importantly, the presented data supports introduction 10 of RET activating therapy at early stages of the disease, both to exert pro-survival effects on DA neurons 11 and to protect them from the development of Lewy pathology. 12
Effect of GDNF on pαSyn accumulation was completely abolished by inhibition of Src kinase but not by 13 inhibition of MAP signaling pathway. Blockade of PI3K or direct blockade of Akt with a specific inhibitor 14 resulted in increase of pαSyn accumulation, which could be partially rescued by the GDNF treatment. 15
In our studies we used MK2206, a highly specific allosteric inhibitor of Akt, not competitive to ATP 16 binding, which was shown to effectively block canonical PI3K/Akt pathway, by preventing T308 and 17 S473 Akt phosphorylation (Manning and Toker, 2017; Meuillet, 2011; Xing et al., 2019) . However, 18
MK2206 does not inhibit kinase domain of Akt directly and, therefore, does not preclude non-canonical 19 activation. 20
Classically, Akt activation by GDNF/RET is thought to be mediated by PI3K signaling in either Src 21 dependent or Src independent manner (Fayard et al., 2011; Kramer and Liss, 2015) . Interestingly, Src is 22 also able to activate Akt through non-canonical PI3K independent pathway by phosphorylating Akt on 1 Y315 and Y326 residues (Mahajan and Mahajan, 2012) , although the role and prevalence of this 2 mechanism is poorly described in literature. In fact, mutated form of RET -RET/PTC (rearranged in 3 transformation/papillary thyroid carcinomas) was shown to promote Y315 and Y326 Akt 4 phosphorylation, presumably through Src activation (Jung et al., 2005) . Moreover, Src can be involved 5 in Akt activation by both PI3K-dependent and -independent pathways even when transducing signal 6 from the same receptor (Lodeiro et al., 2011) . While this pathway has been demonstrated in cancer 7 cells, our data suggest such mechanism may also be involved in GDNF/RET dependent Akt activation in 8 DA neurons. 9
Our results could be explained by PI3K-independent, Src-dependent activation of Akt following 10 GDNF/RET activation. However, we cannot fully rule out that Akt and Src are independently affecting 11 pαSyn accumulation in DA neurons. Therefore, our data warrant further studies of possible PI3K-12 independent, Src-dependent activation of Akt, or other Src-dependent Akt-independent pathways by 13 GDNF and their role in protection against Lewy pathology. Due to limited availability of ligands for 14 dissection of different Akt activation mechanisms, such studies should employ genetically modified Ret, 15
Akt and/or Src. Blocking Akt with MK2206 also resulted in the loss of DA neurons; however, this 16 neuronal loss was similar in control and PFF treated groups. Therefore, the effect was not dependent 17 on pαSyn accumulation and did not impact the interpretation of obtained results. 18
Precise understanding of protective intracellular pathways activated by GDNF in DA neurons is of great 19 importance for engaging RET as a target for PD therapy. For example, putative biased GDNF mimetics, 20
activating Akt through PI3K-independent, Src-dependent pathway may offer an attractive therapy for 21 early PD, protecting against Lewy-pathology, with decreased risks associated with strong Akt activation. 22 1 years due to inconclusive results of clinical trials with GDNF (Paul and Sullivan, 2019) and preclinical and 2 patient data suggesting the loss of RET receptor in later stages of PD (Decressac et al., 2012; Decressac 3 et al., 2013; Decressac et al., 2011) . However, as discussed above, this might not be true for all 4 population of patients, especially those at earlier stages of the disease, and recent clinical trials for 5 GDNF, while not meeting clinical endpoints, demonstrated feasibility of safe, long term GDNF 6 administration (Whone et al., 2019a; Whone et al., 2019b) . Importantly, discussing the modest efficacy 7 of GDNF in the latest clinical studies, the authors suggested future modifications of GDNF trials to 8 increase GDNF dosing or include patients at early stages of PD, what is strongly supported by our data. 9
In addition, less invasive methods of activation of RET receptor together with emerging biomarkers for 10 early PD could provide strategy to prevent disease progression. Actually, GDNF-mimetics are being 11 actively developed (Ivanova et al., 2018; Sidorova et al., 2017) and our data strongly support their 12 potential therapeutic application for the treatment of PD at early stages. 13
Precise mechanism by which activation of RET and downstream pathways reduces accumulation of 14 aggregated α-syn remains unclear. It has been recently proposed that upon their endocytosis, PFFs 15 remain for several days in the endosomal pathway, where they seem to undergo partial processing 16 (Apetri et al., 2016; Flavin et al., 2017) and are subsequently released to the cytoplasm, then promoting 17 fibrillization of endogenous α-syn protein (Bieri et al., 2018) . Therefore, one can speculate that 18 mechanism of RET/Akt action on α-syn could be either interfering with uptake of PFFs, modifying their 19 early processing in endosomal pathway and/or release to cytoplasm, or enhancing clearance of 20 misfolded cytoplasmic α-syn aggregates. Interfering with PFF uptake seems unlikely, as PFFs were 21
shown to be uptaken very rapidly, within hours of application (Karpowicz et al., 2017) , while we show 22 that GDNF was equally effective when applied before and up to 4 days after PFF seeding. Interestingly 1 approximately 5 days after their addition, PFFs were reported to appear in the cytoplasm in neuronal 2 soma, recruiting endogenous α-syn into pSer129-αsyn positive aggregates (Apetri et al., 2016; 3 Karpowicz et al., 2017) . As inhibition of lysosomal processing was shown to accelerate release of PFFs 4 to cytoplasm and recruitment of endogenous α-syn (Karpowicz et al., 2017) , it is possible that RET/Akt 5 activation is altering the processing of the endocytosed fibrils and decreasing their chance of initiating 6 α-syn aggregation in cell soma. Alternatively, activation of GDNF/RET signaling could lead to enhanced 7 clearance of α-syn aggregates, which, if started early when aggregates are few and small, could prevent 8 snowballing increase of α-syn aggregation. 9
Altogether, our results, for the first time, demonstrate that GDNF/RET signaling can protect DA neurons 10 from pathological pαSyn accumulation. Moreover, we show that treatment with neurotrophic factors, 11 or neurotrophic factor mimetics activating the correct intracellular pathways might be effective 12 specifically at the early stage of pathology. These results support early initiation of treatment with 13 neurotrophic factors or neurotrophic factor mimetic in PD patients. 14 15
Materials and Methods 16
Animal experiments 17 63-week-old C57Bl/6NCrI mice (8 males, 6 females) were housed at a 12-hour light-dark cycle, with 18 free access to water and food. All stereotaxic injections were performed under 4% isoflurane. AAVs 19 (AAV1-DIO-iRFP or AAV-GDNF (Penttinen et al., 2018; Richie et al., 2017) ) were injected to the SN (A/P 20 -3.3 mm, M/L -1.2 mm, D/V -4.9 mm from bregma; at 10° angle). One week later, 5 µg of α-syn PFFs (2 21 µg/µL in PBS) were injected to the striatum (A/P 0.7 mm, M/L -2.2 mm, D/V -3.0 mm from bregma). 22
After 4 weeks, the brains were collected after anesthetization of the animals with sodium pentobarbital 1 (Orion Pharma, i.p. 90 mg/kg), followed by intracardial perfusion with PBS and 4% PFA. All animal 2 experiments were approved by the Finnish National Board of Animal Experiments (license number: 3 ESAVI/7812/04.10.07/2015) and were carried out according to the European legislation on the 4 protection of animals used for scientific purposes. 5 6
Immunohistochemistry of free-floating sections 7
The brains were sectioned as described in (Albert et al., 2019) . Briefly, the brains were fixed with 4% 8 PFA, put into a 20% sucrose solution, frozen in a cryostat (Leica CM3050), cut into 40-μm coronal 9 sections covering the striatum (approximately 1.5 to −0.8 mm relative to bregma) and the midbrain 10 (approximately −2.7 to −4.0 mm relative to bregma), and stored in 20% glycerol with 2% DMSO in PBS 11 at −20°C until immunostaining. Every sixth section was used for immunostaining. The sections were 12 thawed at room temperature (RT), rinsed with PBS and after 15 minutes blocking of endogenous 13 peroxidase (0.3% H2O2 in 1:1 PBS:methanol), rinsed twice with 0.3% Triton X-100 in PBS (PBST) and 14 blocked for 1 hour with 5% normal horse serum (NHS; Vector, S-2000) in 0.3% PBST. Sections were 15 incubated with the first primary antibody (monoclonal rabbit anti-phosphoSer129-α-synuclein, Abcam, 16 ab51253; 1:10000) in NHS blocking buffer overnight, at +4°C. Next, sections were rinsed and incubated 17 with the secondary antibody (Vector Laboratories anti-rabbit or anti-mouse biotinylated secondary 18 antibody, PK-4001 and PK-4002; 1:500) in NHS blocking buffer for 1 hour, at RT. After rinsing, sections 19
were incubated in avidin-biotinylated horseradish peroxidase (ABC Kit, Vector Laboratories) in PBST for 20 20 minutes, rinsed, and developed with 3,3-diaminobenzidine-4 HCL (DAB) (DAB peroxidase substrate 21 kit, SK-4100, Vector Laboratories) in water for 2-5 minutes, rinsed with PBS. Following 15 minutes 0.3% 22 H2O2 blocking, sections were rinsed with PBST thrice. Then 15 minutes of Avidin and Biotin incubations 1 (Vector Laboratories, SP-2001) were done. Sections were rinsed thrice and incubated in the second 2 primary antibody (monoclonal mouse anti-TH, Millipore, MAB318; 1:3000) in NHS blocking buffer 3 overnight at +4°C. Same secondary staining steps were repeated except developing, which was done 4
with HistoGreen (HRP substrate kit, E109, Linaris) in water for 1-2 minutes. Sections were rinsed with 5 water and placed on coated glass slides. Slides were allowed to dehydrate overnight at RT and mounted 6
with Coverquick 2000 mounting medium. The slides were digitalized on Pannoramic P250 Flash II Whole 7 Slide Scanner (3DHistech), with 20X magnification (extended focus, 0.22 μm/pixel resolution). The 8 number of LB-like aggregates was counted manually, from 8-9 sections covering the SN. 9
Immunohistochemistry of the sections and quantification of LB-like aggregates were performed by 10 blinded experimenters. 11 12
Primary embryonic midbrain cultures 13
Ventral midbrain floors were isolated from wild-type NMRI E13.5 mouse embryos, as described in 14 (Planken et al., 2010) . Cells were plated in microislands on 96-well plates and incubated in 5% CO2, at 15
37C. 16
Recombinant mouse α-syn PFFs (5 mg/ml) were diluted 1:50 in PBS and sonicated at high power (10 17 cycles, 30 seconds on/ 30 seconds off) with Bioruptor sonicator (Diagenode, Liege, Belgium). On DIV8, 18 2.5 µg/mL of PFFs were added to cultures; 50 ng/ml recombinant GDNF protein (PeproTech, Rocky Hill, 19 NJ, USA or Prospec, CYT-305) was added on DIV8 or DIV12. PBS was used as control. 20
For pathway analyses, 2 µM SU6656 (Src kinase inhibitor) (Tocris, 6475), 10 µM LY294002 (PI-3 kinase 21 inhibitor) (Tocris, 1130), 10 µM U0126 (MEK1/2 inhibitor) (Tocris, 1144), 5 µM MK2206 (Akt kinase 22 inhibitor) (Selleckchem, S1078) in DMSO were added on DIV12, ~45 minutes before GDNF treatment. 1
DMSO was used as vehicle control. 2
On DIV15 the cells were fixed 20 minutes at RT with 4% PFA and stored in PBS at +4ºC until 3 immunostaining. All experimental timelines are stated in corresponding figures. 4 5
Immunohistochemistry of primary embryonic midbrain cultures 6
Fixed plates were rinsed with PBS twice, followed by 15 minutes of permeabilization with 0.2% Triton 7 X-100 in PBS (PBST) and 1 hour of blocking with 5% NHS in PBST. The incubation with primary antibodies 8 (monoclonal mouse anti-TH, Millipore, MAB318 or polyclonal sheep anti-TH, Millipore, ab1542; 9 monoclonal rabbit anti-phosphoSer129-α-synuclein, Abcam, ab51253; rabbit monoclonal anti-Alpha-10 synuclein filament, Abcam, ab209538; all at 1:2000 dilution) in blocking solution was done at +4ºC 11 overnight. Thrice rinse with PBS was done before 1-hour incubation with secondary antibodies (donkey 12 anti-mouse AlexaFluor 488, Thermo Fisher Scientific, A21202 or donkey anti-mouse AlexaFluor 568, 13
Thermo Fisher Scientific, A10037; donkey anti-rabbit AlexaFluor 647, Thermo Fisher Scientific, A31573; 14 1:400), at RT. After PBS rinse, the cells were stained for 10 minutes with 200 ng/ml 4',6-diamidino-2-15 phenylindole (DAPI). Plates were stored at +4ºC until imaging. 16
Imaging of primary cells in 96-well black view plates (PerkinElmer, 6005182) was performed with 17
CellInsight CX5 High Content Scanner (Thermo Fisher Scientific) or ImageXpress Nano Automated 18
Imaging System (Molecular Devices), fitted with 10X objective. From each well 36 (CellInsight CX5) or 9 19 (ImageXpress Nano) view fields were acquired, encompassing entire microisland culture. 20
Quantification of TH-positive cells with or without LB-like pαsyn-positive aggregates was performed 21
with CellProfiler and CellAnalyst software packages (Carpenter et al., 2006; Jones et al., 2009; Jones et 22 al., 2008) . Detailed CellProfiler image analysis pipelines can be provided upon request. Briefly, the first 1 pipeline and CellProfilerAnalyst were used to quantify the numbers of TH-positive cells per well and 2 subsequently classify identified TH-positive cells into LB-positive and LB-negative, utilizing supervised 3 machine learning implemented in CellProfilerAnalyst. 4 5
Statistical analysis 6
In vitro data which was performed in multiple independent experiments (plates) was analyzed utilizing 7 randomized block ANOVA design, matching groups from different plates (Lew, 2007) . Statistical 
